SII gets order for 11 million vaccine doses, trucks ready for transportation
Monday, 11 January 2021 () The process of transporting Covishield vaccine began on Monday after the Serum Institute of India (SII) received the Centre’s initial purchase order for 11 million doses at Rs 200 per dose. This makes the Oxford University-AstraZeneca vaccine, which is being manufactured by SII, the first Covid-19 vaccine to be used for India’s mass immunization programme.
The US Department of Health and Human Services expanded COVID-19 vaccine availability.
The agency said they will now include people age 65 and older in the initial phase of distribution.
According to UPI, the changes also give priority to those with underlying health conditions.
People of any age...
At least 1,65,714 healthcare beneficiaries received COVID-19 jab on Saturday across India, marking it as a historic and biggest COVID-19 vaccination drive launched by Prime Minister Narendra Modi. About 16,755 total vaccinators involved across India during the COVID vaccination drive. There was no post adverse event reported after the vaccination was administered to the people. "Total vaccinators involved across India were 16,755. Total beneficiaries vaccinated across India--1,65,714. COVID19 vaccination drive was successful on Day 1. No case of post-vaccination hospitalisation reported so far," said Manohar Agnani, Additional Secretary of Union Health Ministry. "The Serum Institute of India (SII) produced COVISHIELD was supplied to all States and Union Territories (UT). Bharat Biotech's COVAXIN was supplied to 12 States. Total 3,351 sessions were held across the country with both the vaccines, said Health Ministry on COVID19 vaccine roll-out," he added. Watch the full video for more details.
Credit: HT Digital Content Duration: 06:46Published
On Day 1 of India's Covid-19 vaccination, two doctors who took the shots shared their experience. Dr Atul Peters and Anil Dhar of Max hospital were given Bharat Biotech's Covaxin and SII-made Covishield jabs respectively. Both didn't experience any side-effects and said that doubts regarding the inoculants are unfounded. Dr Suranjit Chatterjee of Apollo hospital, who is set to receive a shot soon, also weighed in on the controversy regarding Covaxin and its third phase trials. Watch the full video for more.
Credit: HT Digital Content Duration: 08:15Published
Additional Secretary of Health Ministry Manohar Agnani informed that a total of 580 adverse events were reported post-vaccination drive. He said, "A cumulative of 580 Adverse Events Following Immunisation (AEFIs) has been reported. Of which 7 have been hospitalised."
After Nepal government approved emergency use of Covishield vaccine, people are hoping the pandemic will falter and human lives would be back on track. Nepal's Department of Drug Administration on Friday issued a release giving information on approving Covishield developed by AstraZeneca and Oxford University, which will be manufactured by Serum Institute of India (SII) in India. Drug regulating authority has also specified Serum Institute of India for importers provided with low cost in purchasing and delivery of vaccine to public. Approving the vaccine for conditional purpose, the department has also asked manufacturers or importers to get approval for registration in order to bring the vaccines. Nepal imposed nationwide and partial lockdown for most of 2020 with rise in imported cases which later took the form of local transmission spreading mostly in urban areas and major cities. The nationwide lockdown which started in March 2020 hampered daily life of people as well as businesses. They now expect to thrive with the approval of vaccine. Though the detailed inoculation plan of Nepal Government is yet to be disclosed, a total of 3 companies applied for approval to take steps forward with Serum Institute for import of vaccines. India has already made conditional emergency approval for Covishield manufactured by the Serum Institute. Being one of the largest producers of vaccines at low cost, India has promised to provide vaccine to its neighbours in near future.
Britain's vaccine rollout is limited by a "lumpy" manufacturing process with production changes by Pfizer and a delay by AstraZeneca that could lead to brief supply disruption, Vaccine Deployment Minister Nadhim Zahawi said on Monday. Ciara Lee reports
Monica Calazans, a 54-year-old nurse in Sao Paulo, became on Sunday the first person to be inoculated in Brazil, receiving the Chinese vaccine known as CoronaVac after Brazilian health regulator Anvisa approved emergency use of COVID-19 vaccines from China's Sinovac Biotech Ltd and Britain's AstraZeneca.
Vaccines minister Nadhim Zahawi has suggested that a gradual easing oflockdown restrictions will not begin before early March. He told BBCBreakfast: “If we take the mid-February target, two weeks after that you getyour protection, pretty much, for the Pfizer/BioNTech, three weeks for theOxford/AstraZeneca, you are protected. “One of the things we don’t know yet,and the deputy chief medical officer Jonathan Van-Tam is on record as saying‘look give me a couple of months and I’ll tell you’, is the impact of thevaccine on transmission rates ie on infecting people. “So there are a numberof caveats that stand in the way of us reopening the economy. “It will begradually, it will be probably through the tiered system but you’re looking atthat sort of period, two to three weeks after the middle of February, afterwe’ve protected the top four cohorts.”
Credit: PA - Press Association STUDIO Duration: 00:53Published
Governor Andrew Cuomo is calling on the federal government to step up its vaccine distribution. This comes as New York is set to receive 250,000 doses of the coronavirus vaccine next week. The governor..
[NFA] U.S. President-elect Joe Biden on Friday said he would order increased production of syringes and other supplies to ramp up vaccinations against COVID-19 and improve upon the Trump administration..